FI874706A0 - Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi - Google Patents

Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi

Info

Publication number
FI874706A0
FI874706A0 FI874706A FI874706A FI874706A0 FI 874706 A0 FI874706 A0 FI 874706A0 FI 874706 A FI874706 A FI 874706A FI 874706 A FI874706 A FI 874706A FI 874706 A0 FI874706 A0 FI 874706A0
Authority
FI
Finland
Prior art keywords
pharmaceutical compositions
stable pharmaceutical
preparation
recombinant interferon
glycosylated recombinant
Prior art date
Application number
FI874706A
Other languages
English (en)
Swedish (sv)
Other versions
FI95002C (fi
FI95002B (fi
FI874706A (fi
Inventor
Ze Ev Shaked
Tracy Stewart
Jody Thomson
James William Thomson
Terrance Taforo
Susan Hershenson
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of FI874706A0 publication Critical patent/FI874706A0/fi
Publication of FI874706A publication Critical patent/FI874706A/fi
Application granted granted Critical
Publication of FI95002B publication Critical patent/FI95002B/fi
Publication of FI95002C publication Critical patent/FI95002C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI874706A 1986-10-27 1987-10-26 Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi FI95002C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92342386A 1986-10-27 1986-10-27
US92342386 1986-10-27

Publications (4)

Publication Number Publication Date
FI874706A0 true FI874706A0 (fi) 1987-10-26
FI874706A FI874706A (fi) 1988-04-28
FI95002B FI95002B (fi) 1995-08-31
FI95002C FI95002C (fi) 1995-12-11

Family

ID=25448670

Family Applications (1)

Application Number Title Priority Date Filing Date
FI874706A FI95002C (fi) 1986-10-27 1987-10-26 Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi

Country Status (9)

Country Link
EP (1) EP0270799B1 (fi)
JP (1) JPS63179833A (fi)
AT (1) ATE111744T1 (fi)
AU (2) AU8019187A (fi)
CA (1) CA1294215C (fi)
DE (1) DE3750574T2 (fi)
DK (1) DK563487A (fi)
FI (1) FI95002C (fi)
NO (1) NO175704C (fi)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
IL89662A (en) * 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
EP0672144A1 (en) * 1992-10-20 1995-09-20 Chiron Corporation Interleukin-6 receptor antagonists
EP0749494A1 (en) 1994-03-07 1996-12-27 Chiron Corporation Compositions for the inhibition of tnf formation and uses thereof
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
GB9506051D0 (en) 1995-03-24 1995-05-10 Univ Singapore Gene expression
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP4293497B2 (ja) 1997-09-23 2009-07-08 レントシュレール ビオテクノロジー ゲー・エム・ベー・ハー インターフェロン−β液状組成物
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7544354B2 (en) 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
JP4129178B2 (ja) 2000-11-07 2008-08-06 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 安定化されたインターフェロン組成物
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
HUP0501111A2 (en) 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
DE602004028643D1 (de) 2003-11-04 2010-09-23 Novartis Vaccines & Diagnostic Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
US20070098718A1 (en) 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
AU2004287480B2 (en) 2003-11-04 2011-09-15 Novartis Vaccines And Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia
WO2005044854A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
US9493514B2 (en) 2011-01-06 2016-11-15 Bionor Immuno As Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes
MX2014014683A (es) 2012-06-06 2015-02-24 Bionor Immuno As Peptidos derivados de proteinas virales para usarse como inmunogenos y reactivos de dosificacion.
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
CN111329450A (zh) 2013-04-23 2020-06-26 雪松-西奈医学中心 用于从荧光团同时录制可见光图像和红外光图像的系统和方法
AU2015206271B2 (en) 2014-01-17 2020-02-27 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
CN106794175B (zh) 2014-06-12 2020-06-09 西达-赛奈医疗中心 用于治疗癌症的组合物
JP6426288B2 (ja) 2014-07-22 2018-11-21 レモネックス インコーポレイテッドLemonex Inc. 生理活性物質又はタンパク質伝達用組成物及びその用途
EP3215186A4 (en) 2014-11-04 2018-10-24 University of Southern California COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
AU2016258984B2 (en) 2015-05-05 2020-11-19 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
EP3345000B1 (en) 2015-08-31 2022-08-31 Cedars-Sinai Medical Center Novel blood cell biomarker for late onset alzheimer's disease
KR20180103817A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
KR101843984B1 (ko) 2016-02-09 2018-03-30 오토텔릭 엘엘씨 췌장암을 치료하기 위한 조성물과 방법
FI126979B (fi) * 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyofilisoitu farmaseuttinen formulaatio ja sen käyttö
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
BR112019016281A2 (pt) 2017-02-06 2020-04-14 Lemonex Inc veículo de substância fisiologicamente ativa
US20210121493A1 (en) 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
AU2018321950A1 (en) 2017-08-22 2020-03-19 Cedars-Sinai Medical Center Compositions and methods for treating cancer
US11530132B2 (en) 2017-09-05 2022-12-20 Lemonex Inc. Composition comprising porous silica particles carrying a cell fate modulating factor
US11690799B2 (en) 2018-04-19 2023-07-04 Lts Lohmann Therapie-Systeme Ag Microneedle system for applying interferon
CN112055582B (zh) * 2018-04-19 2023-09-29 Lts勒曼治疗系统股份公司 用于递送干扰素的微针系统
CN112969711A (zh) 2018-11-08 2021-06-15 西达赛奈医疗中心 使用克拉扎珠单抗脱敏和改善hla致敏患者中的肾脏移植
CN113194996B (zh) 2018-12-20 2024-06-28 西达赛奈医疗中心 克拉扎珠单抗用于治疗慢性抗体介导的器官移植物排斥反应
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55102519A (en) * 1979-01-31 1980-08-05 Green Cross Corp:The Stabilization of interferon
CA1190148A (en) * 1981-10-13 1985-07-09 Samuel S. Asculai Interferon-containing compositions
JPS5910524A (ja) * 1982-07-08 1984-01-20 Toray Ind Inc インタ−フエロン組成物およびその製造法
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
DE3381553D1 (de) * 1982-10-25 1990-06-21 Genentech Inc Synergistische humaninterferonaktivitaet.
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物

Also Published As

Publication number Publication date
DE3750574T2 (de) 1995-02-02
FI95002C (fi) 1995-12-11
AU1063392A (en) 1992-03-19
DK563487D0 (da) 1987-10-27
CA1294215C (en) 1992-01-14
NO175704B (no) 1994-08-15
AU659127B2 (en) 1995-05-11
NO874445L (no) 1988-04-28
ATE111744T1 (de) 1994-10-15
EP0270799A1 (en) 1988-06-15
AU8019187A (en) 1988-04-28
DE3750574D1 (de) 1994-10-27
FI95002B (fi) 1995-08-31
NO175704C (no) 1994-11-23
JPS63179833A (ja) 1988-07-23
EP0270799B1 (en) 1994-09-21
DK563487A (da) 1988-04-28
NO874445D0 (no) 1987-10-26
FI874706A (fi) 1988-04-28

Similar Documents

Publication Publication Date Title
FI874706A0 (fi) Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi
ATE74512T1 (de) Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
DE68924491D1 (de) Intrascheidenabgabe von aktiven Polypeptiden.
KR950703999A (ko) 변성된 인슐린-유사 성장인자(modified insulin-like growth factors)
EP0217645A3 (en) Stable formulation of biologically active proteins for parenteral injection
NO883926D0 (no) Fremgangsmaate for fremstilling av stabilisert humanproteinpreparat.
SE8402560L (sv) Farmaceutisk komposition
DK0759775T3 (da) Flydende IFN-beta-formuleringer
DE3854290D1 (de) Stabilisierung von therapeutisch wirksamen Proteinen in pharmazeutischen Zubereitungen.
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
ES2073063T3 (es) Formulaciones galenicas acuosas de eritropoyetina y su uso.
IT8522442A0 (it) Derivati nucleosidici aventi proprieta' antierpetiche, composizioni farmaceutiche che licontengono e procedimento per lapreparazione degli ingredienti attivi.

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: CETUS CORPORATION

MA Patent expired